Jaguar Health, Inc. Leveraging AI for Breakthrough Therapies in Intestinal Failure Treatment
The global market for Short Bowel Syndrome, including Intestinal Failure (IF), is projected to reach $8.0 billion by 2033. Utilizing AI data mining can help establish connections between genetics, histopathology, and disease progression modification for patients with IF, particularly those with pediatric microvillus inclusion disease (MVID). Jaguar Health, Inc. aims to enhance its crofelemer programs for treating IF in both adult and pediatric patients by leveraging AI platforms to guide personalized regimens and provide real-world evidence supporting the effectiveness of new therapies like crofelemer in managing disease progression. The company is focused on achieving faster commercialization and meeting healthcare delivery objectives for IF indications, including obtaining Breakthrough Therapy designation from the FDA for MVID.
Jaguar Health, Inc., a pharmaceutical company, is dedicated to developing novel prescription medicines derived sustainably from plants in rainforest areas to address gastrointestinal distress in humans and animals. The company's focus is on developing and commercializing crofelemer powder for oral solution to treat rare and orphan gastrointestinal disorders associated with intestinal failure, such as MVID and short bowel syndrome. By exploring AI platforms and advancing its development plan for MVID, Jaguar aims to expedite regulatory submission pathways and address the urgent medical needs of patients with these conditions.
In conclusion, Jaguar Health, Inc. is committed to leveraging AI technology to support its intestinal failure program and accelerate the development and commercialization of crofelemer for rare gastrointestinal disorders like MVID. The company's efforts to obtain Breakthrough Therapy designation from the FDA underscore its dedication to providing efficient and effective treatment options for patients with unmet medical needs in this field.